|
Gene: ADAMTSL3 |
Gene summary for ADAMTSL3 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ADAMTSL3 | Gene ID | 57188 |
Gene name | ADAMTS like 3 | |
Gene Alias | ADAMTSL-3 | |
Cytomap | 15q25.2 | |
Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | P82987 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
57188 | ADAMTSL3 | NAFLD1 | Human | Liver | NAFLD | 8.32e-10 | 6.29e-01 | -0.04 |
57188 | ADAMTSL3 | S41 | Human | Liver | Cirrhotic | 1.19e-05 | 6.24e-01 | -0.0343 |
57188 | ADAMTSL3 | HCC1_Meng | Human | Liver | HCC | 2.02e-11 | -2.07e-01 | 0.0246 |
57188 | ADAMTSL3 | HCC2_Meng | Human | Liver | HCC | 6.30e-04 | -2.03e-01 | 0.0107 |
57188 | ADAMTSL3 | cirrhotic1 | Human | Liver | Cirrhotic | 5.99e-03 | -1.98e-01 | 0.0202 |
57188 | ADAMTSL3 | cirrhotic2 | Human | Liver | Cirrhotic | 5.48e-03 | -1.98e-01 | 0.0201 |
57188 | ADAMTSL3 | HCC2 | Human | Liver | HCC | 9.48e-04 | 3.23e+00 | 0.5341 |
57188 | ADAMTSL3 | Pt13.b | Human | Liver | HCC | 2.55e-06 | -3.38e-02 | 0.0251 |
57188 | ADAMTSL3 | Pt14.d | Human | Liver | HCC | 1.90e-02 | -2.05e-01 | 0.0143 |
57188 | ADAMTSL3 | S029 | Human | Liver | HCC | 2.17e-03 | 5.84e-02 | 0.2581 |
57188 | ADAMTSL3 | GSM5353221_PA_PB2A_Pool_1_3_S25_L001 | Human | Prostate | Tumor | 5.78e-12 | 6.35e-01 | 0.1633 |
57188 | ADAMTSL3 | GSM5353222_PA_PB2B_Pool_1_3_S52_L002 | Human | Prostate | Tumor | 1.19e-20 | 7.97e-01 | 0.1608 |
57188 | ADAMTSL3 | GSM5353223_PA_PB2B_Pool_2_S26_L001 | Human | Prostate | Tumor | 3.39e-11 | 6.86e-01 | 0.1604 |
57188 | ADAMTSL3 | GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001 | Human | Prostate | Tumor | 4.67e-04 | 3.81e-01 | 0.1621 |
57188 | ADAMTSL3 | GSM5353240_PA_PR5254_T1_S15_L001 | Human | Prostate | Tumor | 3.69e-04 | 3.43e-01 | 0.1575 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease | ||
Prostate | BPH: Benign Prostatic Hyperplasia |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ADAMTSL3 | SNV | Missense_Mutation | novel | c.629N>T | p.Ser210Ile | p.S210I | P82987 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-MX-A5UJ-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ADAMTSL3 | SNV | Missense_Mutation | novel | c.4837N>C | p.Cys1613Arg | p.C1613R | P82987 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-VQ-A8P2-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unspecific | Complete Response | |
ADAMTSL3 | SNV | Missense_Mutation | novel | c.3705N>T | p.Gln1235His | p.Q1235H | P82987 | protein_coding | tolerated(0.23) | possibly_damaging(0.832) | TCGA-VQ-A91K-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | fluorouracil | CR |
ADAMTSL3 | SNV | Missense_Mutation | c.2240A>C | p.Lys747Thr | p.K747T | P82987 | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-VQ-A91S-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | fluorouracil | CR | |
ADAMTSL3 | SNV | Missense_Mutation | novel | c.3239N>A | p.Phe1080Tyr | p.F1080Y | P82987 | protein_coding | tolerated(0.56) | benign(0.196) | TCGA-VQ-A91V-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | cisplatin | PD |
ADAMTSL3 | insertion | Nonsense_Mutation | novel | c.4093_4094insCTTAAAATAAAGATAGATAAGA | p.Tyr1365SerfsTer2 | p.Y1365Sfs*2 | P82987 | protein_coding | TCGA-CD-5798-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | ||
ADAMTSL3 | SNV | Missense_Mutation | c.1870N>A | p.Ala624Thr | p.A624T | P82987 | protein_coding | tolerated(0.07) | benign(0.341) | TCGA-BJ-A0ZB-01 | Thyroid | thyroid carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
ADAMTSL3 | SNV | Missense_Mutation | novel | c.756N>T | p.Leu252Phe | p.L252F | P82987 | protein_coding | tolerated(0.05) | benign(0.163) | TCGA-FY-A3BL-01 | Thyroid | thyroid carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ADAMTSL3 | insertion | Frame_Shift_Ins | novel | c.4152_4153insACAAATACCATTCACTGTTTTGA | p.Leu1385ThrfsTer77 | p.L1385Tfs*77 | P82987 | protein_coding | TCGA-EL-A3ZR-01 | Thyroid | thyroid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |